Tokyo Tape
Sign in
← Sapporo Clinical Laboratory

Quarterly report · Q1

9776.TEDINET S100RLX2
Period2023-04-01 → 2023-06-30
Filed2023-08-09
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥4.9bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥20.1bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥4.9bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥76m2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥132m2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥81m2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥1.2bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥223m2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥74m2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥222m2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥6m2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥569m2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥78m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥9m2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥125m2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥16.7bnat 2023-06-30Cons.Assets
Total assets¥16.5bnat 2023-03-31Cons.Assets
Total assets¥16.2bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥5.9bnat 2023-06-30Cons.Liabilities
Total liabilities¥5.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥10.8bnat 2023-06-30Cons.Net assets
Net assets / equity¥10.9bnat 2023-03-31Cons.Net assets
Net assets / equity¥10.4bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥3.8bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥3.7bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥1.722023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥170.532022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥23.352022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio63.2%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio64.1%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.3%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-06-30¥18m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-06-30¥18m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-06-30¥855,000
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-06-30¥12m
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥1.9bn
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥1.9bn
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥62m
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥2.7bn
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥2.7bn
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥108m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥431m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥265m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥166m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentsegment profit2023-04-01 → 2023-06-30−¥4m
—segment totalrevenue2023-04-01 → 2023-06-30¥5.1bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥4.9bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥166m
—segment totalsegment profit2023-04-01 → 2023-06-30¥166m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-06-30¥5.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-06-30¥4.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-06-30¥167m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-06-30¥178m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥23m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥22m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥846,000
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30¥15m
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥200m
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.5bn
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.5bn
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥78m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥376m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥233m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥143m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentsegment profit2022-04-01 → 2022-06-30−¥3m
—segment totalrevenue2022-04-01 → 2022-06-30¥5.0bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥4.9bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥143m
—segment totalsegment profit2022-04-01 → 2022-06-30¥275m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥5.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥4.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥144m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥290m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 376
ItemContextValueUnit
Transactions with other segmentsPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember846000JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember143836000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E04950-000ClinicalTestingBusinessReportableSegmentsMember2096762000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember2548224000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E04950-000MedicalDevicesSalesAndMaintenanceBusinessReportableSegmentsMember375661000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember5020648000JPY
Net salesPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember23238000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember5043886000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E04950-000ClinicalTestingBusinessReportableSegmentsMember199981000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember77845000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E04950-000MedicalDevicesSalesAndMaintenanceBusinessReportableSegmentsMember-2699000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember275127000JPY
Operating incomePrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember15288000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember290416000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E04950-000ClinicalTestingBusinessReportableSegmentsMember1937360000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember2702566000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E04950-000MedicalDevicesSalesAndMaintenanceBusinessReportableSegmentsMember265155000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember4905082000JPY
Revenues from external customersCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember17511000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember4922593000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E04950-000ClinicalTestingBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E04950-000MedicalDevicesSalesAndMaintenanceBusinessReportableSegmentsMember166244000JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember166244000JPY
Transactions with other segmentsCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember855000JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember167099000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E04950-000ClinicalTestingBusinessReportableSegmentsMember1937360000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember2702566000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E04950-000MedicalDevicesSalesAndMaintenanceBusinessReportableSegmentsMember431399000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember5071326000JPY
Net salesCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember18366000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember5089693000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E04950-000ClinicalTestingBusinessReportableSegmentsMember62168000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember107671000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E04950-000MedicalDevicesSalesAndMaintenanceBusinessReportableSegmentsMember-4021000JPY
Operating incomeCurrentYTDDuration_ReportableSegmentsMember165818000JPY
Operating incomeCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember12325000JPY
Operating incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember178144000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)北海道財務局長
Filing date cover pageFilingDateInstant2023-08-09
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第60期第１四半期（自　2023年４月１日　至　2023年６月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)札幌臨床検査センター株式会社
Company name in english cover pageFilingDateInstantSAPPORO CLINICAL LABORATORY INC.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　伊達　忠應
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)札幌市中央区北三条西十八丁目２番地２
Telephone number address of registered headquarter cover pageFilingDateInstant０１１（６１３）３２１０
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)総務部長　南　誠
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)札幌市中央区北三条西十八丁目２番地２

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass